HomeCompareSZIHF vs JNJ

SZIHF vs JNJ: Dividend Comparison 2026

SZIHF yields 8.52% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $9.1K in total portfolio value· pulled ahead in Year 7
10 years
SZIHF
SZIHF
● Live price
8.52%
Share price
$0.90
Annual div
$0.08
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.2K
Annual income
$0.90
Full SZIHF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — SZIHF vs JNJ

📍 JNJ pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSZIHFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SZIHF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SZIHF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SZIHF
Annual income on $10K today (after 15% tax)
$724.21/yr
After 10yr DRIP, annual income (after tax)
$0.77/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,985.23/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SZIHF + JNJ for your $10,000?

SZIHF: 50%JNJ: 50%
100% JNJ50/50100% SZIHF
Portfolio after 10yr
$25.7K
Annual income
$2,345.15/yr
Blended yield
9.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

SZIHF
No analyst data
Altman Z
0.5
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SZIHF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSZIHFJNJ
Forward yield8.52%2.13%
Annual dividend / share$0.08$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%28%
Portfolio after 10y$21.2K$30.3K
Annual income after 10y$0.90$4,689.40
Total dividends collected$873.00$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SZIHF vs JNJ ($10,000, DRIP)

YearSZIHF PortfolioSZIHF Income/yrJNJ PortfolioJNJ Income/yrGap
1$11,126$426.01$10,592$272.30+$534.00SZIHF
2$12,126$221.48$11,289$357.73+$837.00SZIHF
3$13,088$112.80$12,123$472.89+$965.00SZIHF
4$14,061$56.89$13,141$629.86+$920.00SZIHF
5$15,074$28.56$14,408$846.81+$666.00SZIHF
6$16,143$14.31$16,021$1,151.60+$122.00SZIHF
7← crossover$17,281$7.16$18,122$1,588.22$841.00JNJ
8$18,494$3.58$20,930$2,228.20$2.4KJNJ
9$19,790$1.79$24,792$3,191.91$5.0KJNJ
10$21,176$0.90$30,274$4,689.40$9.1KJNJ

SZIHF vs JNJ: Complete Analysis 2026

SZIHFStock

Shenzhen International Holdings Limited, an investment holding company, invests in, constructs, and operates logistic infrastructure facilities primarily in the People's Republic of China. It operates through two segments, Toll roads and General Environmental Protection Business, and Logistic Business. The Toll roads and General Environmental Protection Business segment develops, operates, and manages toll highways. This segment also engages in the sale of wind turbine equipment; kitchen waste disposal projects construction; and operation and sale of wind power stations. The company's Logistic Business segment constructs, operates, and manages logistics parks and centers, and integrated logistics hubs; and provides third-party logistics services, logistic information services, and financial services; port and related services; and logistic park transformation and upgrading services. It also operates two general bulk cargo terminals and depots in Nanjing Xiba Port that provides various services, such as loading and unloading, lightering, train loading and unloading, and warehousing. In addition, the company provides electronic information exchange, transmission, and value-added information sharing services; supply chain management services; project investment and enterprise management consulting services; and real estate development and investment management services, as well as operates Longda and Shenzhen Expressway in Shenzhen. Further, it offers logistics and transportation ancillary services, and cargo transportation and warehousing services. Additionally, it provides technical development, sales, maintenance, and technology service of computer hardware, software, and network systems; and monetary and financial leasing, property leasing and management, freight forwarding, and other services. The company is headquartered in Tsimshatsui East, Hong Kong.

Full SZIHF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this SZIHF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SZIHF vs SCHDSZIHF vs JEPISZIHF vs OSZIHF vs KOSZIHF vs MAINSZIHF vs ABBVSZIHF vs MRKSZIHF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.